MicroRNA, Diabetes Mellitus and Colorectal Cancer

Wang, Hsiuying

doi:10.3390/biomedicines8120530

Cited by 20 publications

(12 citation statements)

References 172 publications

(178 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Abnormal expression of miRNAs has been observed in many different types of human cancers, including CRC. A large number of differentially expressed miRNAs have been observed in CRC, most of which are related to CRC development, progression, and treatment response (Stiegelbauer et al, 2014; Tan et al, 2018; Wang, 2020). The changes in miRNA expression are associated with metastasis of cancer, the growth of the mass, and increasing malignancy of the cancer cells (Muhammad et al, 2014).…”

Section: Discussionmentioning

confidence: 99%

Targeting of MAD2L1 by miR‐515‐5p involves the regulation of cell cycle arrest and apoptosis of colorectal cancer cells

Ding

Chen

et al. 2022

Cell Biology International

View full text Add to dashboard Cite

Although many previous studies have found that the mitotic arrest deficient 2-like 1 (MAD2L1) protein contributes to the proliferation of colorectal cancer (CRC) cells, but the upstream mechanism of MAD2L1 is still largely elusive. This study aimed to explore the microRNAs (miRNAs) upstream of MAD2L1 to improve our understanding of the mechanism of the MAD2L1 gene in CRC. The upstream target miRNAs (miR-515-5p) of MAD2L1 were predicted by the online databases miRWalk, miRDIP, and TargetScan. Quantitative real-time PCR (qRT-PCR) was used to detect the expression level of miR-515-5p in human CRC tissues. The targeting relationship between miR-515-5p and MAD2L1 was tested by dual luciferase reporter gene assays. The effects of miR-515-5p on the biological behaviors of CRC cells by regulating MAD2L1 expression were verified by qRT-PCR, western blot, Cell Counting Kit-8, and flow cytometry. The results showed that miR-515-5p was a highly reliable upstream miRNA of the MAD2L1 gene. As an upstream target miRNA of MAD2L1, miR-515-5p was lowly expression in CRC tissues. The overexpression of miR-515-5p could inhibit the proliferation of CRC cells and induce cell cycle arrest at the G1 phase leading to cell apoptosis. However, MAD2L1 gene overexpression could reverse the effects of miR-515-5p overexpression on the biological behaviors of CRC cells above. This study illustrated that miR-515-5p can inhibit proliferation and induce G1 phase arrest leading to apoptosis in CRC cells. The mechanism underlying this phenomenon may be related to the negative targeted regulation of MAD2L1.

show abstract

Section: Discussionmentioning

confidence: 99%

Targeting of MAD2L1 by miR‐515‐5p involves the regulation of cell cycle arrest and apoptosis of colorectal cancer cells

Ding

Chen

et al. 2022

Cell Biology International

View full text Add to dashboard Cite

show abstract

“…The miR-365 appeared to be greatly expressed in invasive ductal adenocarcinoma and to cause gemcitabine resistance among the cancer cells in pancreas by directly aiming the adaptor proteins Src homology 2 domain comprising 1 and BAX, which promote apoptosis (Hamada et al, 2014). Furthermore, the expression of miR-365 was shown to be lower in colon cancer cell lines, and restoring it inhibited cell cycle progression, increased 5-fluorouracil-induced apoptosis, and reduced tumorigenicity (Wang, 2020). According to a modern study, miR-365 expression is negatively associated with weak prognosis and survival rates in individuals with HCC due to its ability to limit cell proliferation (Chen et al, 2015).…”

Section: Since 1990mentioning

confidence: 99%

Some Biochemical Changes and Role of Micro RNA 34 a-5p and Micro RNA 365a-5p as A Diagnostic Marker in Chronic Hepatitis C (HCV).

Mohamed

Mahfouz

Amin

et al. 2022

Benha Veterinary Medical Journal

View full text Add to dashboard Cite

This study aimed to investigate Micro RNA 34a-5p and Micro RNA 365a-5p in addition to the traditional biochemical analysis as a useful diagnostic biochemical marker for chronic Hepatitis C Virus (HCV). The present study included 17 individuals with chronic liver disease, who admitted to Benha University Hospital. After investigating 5 patients from all patients, were found to be positive polymerase chain reaction (PCR) chronic HCV. 10 control negative serum samples were collected from the control healthy group. Biochemical analysis was done for investigating liver function parameters alanine transaminase (ALT), aspartate transaminase (AST), total bilirubin (TBil), direct bilirubin (DBil), gama glutamyl transferase (GGT), alkaline phosphatase (ALP) and albumin (Alb) and hematological analysis including total leucocytic count (TLC), hemoglobuin concentration (Hb) and platelet count (PLT), Alpha feto protein (AFP) as a tumor marker indicator. RNA was extracted from serum samples for gene expression of microRNA34 a-5p and microRNA 365a-5p. HCV group showed a significant increase in liver function parameters (ALT, AST, TBIL, DBIL, GGT, ALP) while there was a significant reduction in the albumin levels. Moreover, there was a significant decrease in TLC with non-significant decrease in the HB concentration and the platelet count. AFP concentration in HCV group was significantly increased compared to the control group. HCV group revealed a significant increase (8.98 ± 0.34) in miRNA34, with a significant decrease in miRNA365 (0.25 ± 0.03). We concluded that miRNA34a-5p and miRNA365a-5p expressions in addition to different biochemical analysis can be used as a useful diagnostic marker for HCV diagnosis.

show abstract

“…For neurological diseases, miRNAs were identified to account for PD, amyotrophic lateral sclerosis, frontotemporal dementia, Alzheimer’s disease, spinal muscular atrophy, Prader–Willi syndrome, Niemann–Pick disease, neurofibromatosis, narcolepsy, Friedreich’s ataxia, and ataxia-telangiectasia [ 36 , 37 , 38 , 39 , 40 , 41 ]. miRNAs are also explored as being related to DM [ 42 ].…”

Section: Micrornamentioning

confidence: 99%

MicroRNAs, Parkinson’s Disease, and Diabetes Mellitus

Wang

2021

IJMS

Self Cite

View full text Add to dashboard Cite

Parkinson’s disease (PD) is a neurodegenerative disorder that affects 1% of the population over the age of 60. Diabetes Mellitus (DM) is a metabolic disorder that affects approximately 25% of adults over the age of 60. Recent studies showed that DM increases the risk of developing PD. The link between DM and PD has been discussed in the literature in relation to different mechanisms including mitochondrial dysfunction, oxidative stress, and protein aggregation. In this paper, we review the common microRNA (miRNA) biomarkers of both diseases. miRNAs play an important role in cell differentiation, development, the regulation of the cell cycle, and apoptosis. They are also involved in the pathology of many diseases. miRNAs can mediate the insulin pathway and glucose absorption. miRNAs can also regulate PD-related genes. Therefore, exploring the common miRNA biomarkers of both PD and DM can shed a light on how these two diseases are correlated, and targeting miRNAs is a potential therapeutic opportunity for both diseases.

show abstract

MicroRNA, Diabetes Mellitus and Colorectal Cancer

Cited by 20 publications

References 172 publications

Targeting of MAD2L1 by miR‐515‐5p involves the regulation of cell cycle arrest and apoptosis of colorectal cancer cells

Targeting of MAD2L1 by miR‐515‐5p involves the regulation of cell cycle arrest and apoptosis of colorectal cancer cells

Some Biochemical Changes and Role of Micro RNA 34 a-5p and Micro RNA 365a-5p as A Diagnostic Marker in Chronic Hepatitis C (HCV).

MicroRNAs, Parkinson’s Disease, and Diabetes Mellitus

Contact Info

Product

Resources

About